Exposure to tobacco smoke is one of the best studied examples of an exposure with proven causal association with a large number of human diseases[@b1]. Although the relevant epidemiological evidence is not completely consistent, many studies have provided evidence of differential sex susceptibility to the health effects of tobacco, especially in relation to smoking-induced cardiovascular disease (CVD; including acute myocardial infarction and coronary heart disease)[@b2][@b3][@b4], chronic obstructive pulmonary disease (COPD)[@b1][@b5][@b6] and lung cancer[@b7][@b8][@b9]. Focusing in particular on CVD, a systematic review and meta-analysis of data from 86 prospective studies and nearly 4 million subjects came to the conclusion that female smokers have a 25% higher risk of developing coronary heart disease than males with the same exposure to tobacco smoke and after allowing for other risk factors[@b2], a conclusion supported by the results of a recent meta-analysis of the available data[@b3]. Another recent systematic review and meta-analysis covering data from 81 cohorts and nearly 4 million subjects concluded that the risk of stroke in Western populations is 10% higher in female smokers[@b4].

Biomarker-based investigations have contributed significantly to our understanding of the disease risks associated with exposure to environmental hazards. Currently such biomarker studies are benefiting from the expanding use of genome-wide profiling (omics). We have recently reported the results of a study of the impact of tobacco smoke exposure on genome-wide gene expression and DNA methylation in white blood cells (WBCs) of apparently healthy smokers[@b10] and identified large numbers of transcripts and DNA CpG sites whose expression and methylation, respectively, differ significantly between current and never smokers. Furthermore we used disease connectivity analysis to show that the corresponding gene profiles can identify with remarkable efficiency (specificity 94%, positive predictive value 86%) most diseases and conditions independently known to be causally associated with smoking[@b10]. In view of this finding, we decided to look for sex-related differences in these profiles which might possibly reflect differential disease susceptibility.

Results
=======

In order to minimise statistical power problems, we focused our search for sex-related differences in the effects of tobacco smoking on the transcriptomic and epigenetic features which we previously found to differ significantly between mixed-sex groups of current and never smokers[@b10]. These features consist of 1,273 CpG sites (FDR \< 0.05; associated with 725 differentially methylated genes - DMGs) and 350 transcripts (FDR \< 0.10; associated with 271 differentially expressed genes - DEGs) which were derived from the comparison of genome-wide transcriptomic and epigenetic profiles of 143 current and 311 never smokers (including 134 males and 320 females) derived from 2 cohorts, the Northern Sweden Health and Disease Study and EPIC Italy ([Suppl. Tables S1 and S2](#S1){ref-type="supplementary-material"}).

The tobacco exposure data available to us ([Table 1](#t1){ref-type="table"}) included the number of cigarettes smoked per day and smoking duration in both cohorts, the smoking intensity measured in pack-years (only in the Italian cohort), as well as plasma cotinine levels for a fraction of the study subjects from both cohorts. Inspection of this data did not reveal statistically significant differences between the two sexes, although it did suggest possibly higher exposure intensity (pack-years) in males ([Table 1](#t1){ref-type="table"}). While the above parameters provide an approximate picture of smoking exposure, they do not allow an accurate quantitative estimation of the long-term exposure to tobacco smoke of the different subjects suitable for use in statistical adjustment for the purpose of sub-group comparison. For this reason, and also having in mind our previous observation of the highly skewed distribution of the expression or methylation differences between current and never smokers (effect size), we opted to base our sex comparisons not on the effect size, which is expected to be strongly dependent on exposure level and duration, but on the ranking of the various features by statistical significance (i.e. p-values in current vs never smoker comparisons) in sex-stratified analyses. Thus we compared the full set of signals separately for males and females, ranking them according to the statistical significance of their current-versus-never smoker differences in each sex and, finally, compared the rankings in the two sexes of the limited number of signals of interest. The methodology is described in detail in Methods while the workflow of the procedure is shown diagrammatically in [Fig. 1](#f1){ref-type="fig"}. We adopted this approach on the reasonable assumption that any differences between the sexes with regard to the level or duration of exposure would in general affect the effect size for the different features in a similar manner but would be unlikely to alter their ranking within each sex group. This non-parametric approach has the added advantage that it minimizes the impact of non-normal data distribution, outliers and differences in statistical power arising from the different sizes of the male and female populations.

[Suppl. Fig. S1](#S1){ref-type="supplementary-material"} shows the distribution of the p-values of the rank differences in the two sexes. It can be seen that a biomodal distribution is observed, with the anticipated pattern of decreasing numbers of signals as p-values decrease being observed along with an increased number of signals with very low p-values (\<0.05) increases. The latter indicates the existence, among both the transcriptomic and the epigenetic signals, of sub-groups of signals whose ranking differences between the sexes are more significant than expected.

[Tables 2](#t2){ref-type="table"} and [3](#t3){ref-type="table"} show the lists of expression probes and CpG sites, respectively, whose significance rankings differ significantly (p \< 0.05) between the two sexes. There was no significant difference in the corresponding rankings of these signals between male and female never smokers (results not shown), indicating that the observed sex-related differences reflect the differential impact of tobacco smoke exposure.

Expression profile
------------------

All 26 expression probes in [Table 2](#t2){ref-type="table"} show large ranking differences between the sexes, with 23 exhibiting higher significance in females (median ranks: 111 in females and 19,775 in males), while the remaining 3 probes show higher significance in males. All probes are underexpressed in smokers with the exception of 2 which are overexpressed particularly in male smokers. Owing to population size limitations, many of the identified signals do not reach statistical significance in the sex-stratified analyses. However, for the 23 female-specific probes, the median FDR value with regard to the current-versus-never smoker comparisons is 0.40 (range 0.01--0.91) in females while all 23 have FDR \> 0.80 in males (not shown), suggesting that the effects of smoking are largely limited to females. Importantly, as shown in [Table 2](#t2){ref-type="table"} these significance ranking differences are accompanied by a corresponding difference in effect sizes for all the signals identified, with the median effect size (ratio of expression in current divided by never smokers) observed being 0.80 (range 0.72--0.93) and 0.96 (range 0.93--1.00) in females and males, respectively. No expression probe shows opposite effects of smoking in the two sexes.

Epigenetic profile
------------------

Turning to the epigenetic profile, the 92 CpG sites (associated with 72 genes) thus identified ([Table 3](#t3){ref-type="table"}) show both under- and overmethylation in smokers while their ranking differences between the sexes are also substantial, with the median rank values being 432 and 215,917 in females and males, respectively. The median FDR value of these CpG sites is 0.12 (range 0.0002--0.68) in females, while all 92 sites have FDR \> 0.9 in males. In complete analogy to what is observed for the transcriptomic profile, for all CpG sites the impact of smoking (Δβ = β~smokers~ − β~non-smokers~) is greater in females than in males, with the median absolute Δβ values being 1.55% (range 0.15--8.45%) and 0.33% (range 0.00--8.45%), in females and males, respectively. No CpG sites exhibit opposite effects of smoking in the two sexes. There was no statistically significant overabundance in the distribution of the CpG sites in relation to their locations (TSS200, TSS1500, body, 3′UTR, 5′UTR, 1st exon, intragenic) or to their occurrence in CpG islands and their regions (island, non-island S-shore, S-shelf, N-shore, N-shelf). Finally, we note that one gene, PLIN5, appears to be more overexpressed in females but more undermethylated in males, implying a possibility of differential epigenetic regulation in the two sexes.

Consistency and stability of observed sex effects
-------------------------------------------------

Owing to the limited population size no direct replication between the two cohorts was conducted. However, cohort-stratified analyses show that the features listed in [Tables 3](#t3){ref-type="table"} and [4](#t4){ref-type="table"} tend to be among the most significant features, in terms of sex differences, also in the individual cohorts. Thus, the median rank value of the 92 CpG sites of [Table 4](#t4){ref-type="table"} was 3,048 (out of a total of 410,987 sites examined; top 0.7%) in females and 195,213 in males in NSHDS, and 9,098 (top 2%) and 218,704, respectively, in EPIC Italy, thus demonstrating a clear trend of higher female sensitivity in both cohorts. A similar trend was seen with the corresponding transcriptomic signals of [Table 2](#t2){ref-type="table"}, with the 23 female-specific signals having median ranks of 585 (out of a total of 29,667 probes examined; top 2%) in females and 25,742 in males in NSHDS, and 1,708 (top 6%) and 12,338 in females and males, respectively, in EPIC Italy. As regards the 3 male-specific transcriptomic signals, all 3 in NSHDS and 2 out of 3 in EPIC ranked higher in males.

The observation that almost all sex-specific features identified show higher sensitivity in females is striking. For comparison it is noted that only 116 of the 350 transcripts and 1,009 of the 1,273 CpGs differentially modified by smoking in the mixed population have lower FDR values in females. Although, as stated above, the rank-based comparison we employed is not expected to be significantly affected by group size, in view of the larger number of females in our study (320 female versus 134 male current and never smokers), we ran the same analysis as described above 10 times, in each case using all 134 male subjects and an equal number of females sampled randomly from our population while maintaining constant the proportions of subjects coming from each of the two cohorts and with the different types of smoking status (see [Fig. 1](#f1){ref-type="fig"}, right). In each such resampling analysis, the resulting sex-specific epigenetic or transcriptomic signals included on average 50.3% (S.D. 7.3%) and 50.8% (S.D. 14.2%) of the signals shown in [Tables 2](#t2){ref-type="table"} and [3](#t3){ref-type="table"}, respectively, while the cumulative % overlap (average of each successive resampling round plus all preceding ones) for both lists tended towards approx. 50%, reflecting the similar loss of statistical power of the smaller subpopulations employed ([Suppl. Table S3](#S1){ref-type="supplementary-material"} and [Suppl. Fig. S2](#S1){ref-type="supplementary-material"}). These observations provide confirmation that the identification of the sex-specific signals was not subject to bias by the group size of each sex class.

Discussion
==========

A number of recent studies on smoking-induced changes in methylation profiles, which employed effect size as the response classification parameter, failed to detect any sex-specific responses[@b11][@b12], possibly because of residual confounding arising from insufficiently accurate adjustment for tobacco smoke exposure. By comparing in sex-stratified analyses the significance ranking of transcriptomic and epigenetic signals previously shown to differ between current and never smokers in a mixed-sex population, we identified a number of features which exhibit significantly different responses in the two sexes. Because the highly stringent nature of our non-parametric, rank-based statistical methodology inevitably attenuates sensitivity, it is possible that additional features with sex-specific behaviour may exist. On the other hand this approach has the advantage that it minimizes false positive findings and maximizes specificity.

Our observation that almost all features identified show stronger responses in females implies the possibility of higher female susceptibility to diseases related to the corresponding genes. The most notable observation regarding the list of sex-specific DEGs and DMGs relates to the presence of multiple genes related to CVD, especially genes involved in thrombin signaling and vascular and endothelial cell function. [Table 4](#t4){ref-type="table"} summarises the relevant evidence (discussed further below) and compares the changes observed in the present study with those reported in clinical studies, where such information is available. It can be seen that the direction of change reported in these studies is in concordance with that which we have observed in apparently healthy female smokers, supporting the relevance of these changes to disease pathogenesis.

Genes involved in thrombin signaling
------------------------------------

Thrombin, a serine protease, has an essential role in coagulation and haemostasis mediated by platelets, while in addition it elicits important effects in endothelial and vascular smooth muscle cells (VSMC). For these reasons thrombin-mediated effects are of great importance in the pathogenesis of CVD. Most of the cellular effects of thrombin are initiated via the activation of a family of G-protein-coupled receptors called protease-activated receptors (PARs), which are transmembrane proteins expressed on different types of cells including platelets, endothelial cells and VSMC. The main thrombin receptor on platelets and blood vessel cells is PAR1, also known as coagulation factor II (thrombin) receptor (F2R). This gene plays a key role in vascular function and CVD[@b13] and its genetic variants are known to influence platelet function[@b14][@b15]. In our previously published analysis of the effects of smoking on transcriptomic and epigenetic profiles[@b10] we found F2R to be differentially underexpressed in current smokers with a statistical significance of FDR = 0.15 which just fails to reach the threshold adopted in the present analysis (FDR \< 0.10). Inclusion of the F2R-related expression probe together with the 350 probes with FDR \< 0.10 in the sex-stratified analysis described above reveals a highly significant female specificity of the effect of smoking on this gene. Thus, in male- and female-stratified analyses, respectively, the significance rankings for current-versus-never-smoker comparisons were 29,197 and 1,283 (p = 1.08 × 10^−4^), the FDR values 0.98 and 0.040 and the effect sizes 1.00 and 0.88.

The interaction of thrombin with PAR1 in platelets is facilitated by its initial binding to the GPIb-IX-V complex which plays a critical role in thrombosis, atherogenesis and inflammation[@b16]. This complex includes the glycoprotein GP5, which is associated with a CpG site we found to be differentially overmethylated in female smokers ([Table 3](#t3){ref-type="table"}). Following its activation via the cleavage of its N-terminal domain by thrombin, PAR1 initiates multiple kinase signaling pathways which lead to different effects depending on the cells concerned ([Fig. 2](#f2){ref-type="fig"}). Such effects include hemostasis and thrombosis in the case of platelets, induction of pro-inflammatory phenotype in the case of endothelial cells, increase of vascular permeability, proliferation, migration and hypertrophy in the case of VSMCs, thus contributing to the pathogenesis of different types of CVD.

Signaling by the activated PAR1 receptor is controlled by, among other factors, Src kinases[@b17], including FYN (FYN proto-oncogene, Src family tyrosine kinase) which is associated with a CpG site differentially undermethylated in female smokers. Following initiation of GPIb-IX-V/PAR1 signalling, FYN phosphorylates PKCδ (protein kinase Cδ) which subsequently negatively modulates platelet activation[@b18]. The importance of FYN for haemostasis-related disease is underlined by the report that FYN-deficient mice show an altered haemostatic response[@b19].

Another gene which influences platelet function is IGF1R (insulin-like growth factor 1 receptor), which is associated with a CpG site differentially overmethylated in female smokers. The IFG1R protein is expressed at high levels on the plasma membrane of platelets while its ligand, IGF1, is a growth factor found in the α granules in platelets. Stimulation of platelets with IGF1 results in rapid phosphorylation of IGF1R and potentiation of PAR1-induced platelet aggregation[@b20].

As already mentioned, thrombin-mediated PAR (including PAR1) signaling also operates in VSMC and endothelial cells, thereby playing an important role in diverse cellular activities related to inflammation, CVD, tumor growth and other conditions. In this context the genes discussed above (with the exception of GP5 which is expressed only in platelets) can be anticipated to affect by analogous mechanisms the pathogenesis of such diseases. Moreover, a number of additional genes of relevance to thrombin signaling in VSMC and endothelial cells is included in the list of genes found to be differentially modified in female smokers. One of these genes is EGF (epidermal growth factor), differentially overmethylated in female smokers, a potent mitogenic factor in many cell types acting through its receptor EGFR. Activation of EGFR promotes thrombin-induced proliferation of VSMC[@b21], while its inhibition attenuates thrombin-stimulated signalling along the PI3K-Akt-mTOR-S6K1 axis, leading to effects on cell proliferation and motility[@b22]. Importantly, EGFR signalling is coordinated by EPS8 (epidermal growth factor receptor pathway substrate 8)[@b23], which is underexpressed in female smokers. In support of a probable role of EPS8 in vascular disease is the report that EPS8-null mice show increased vascular permeability[@b24]. Finally, RPTOR (regulatory associated protein of MTOR, complex 1), overmethylated at 2 CpG sites in female smokers, negatively regulates mTOR kinase[@b25] which, as mentioned above, is involved in thrombin signaling in VSMC. It is noted that mice with an RPTOR deletion targeted on the myocardium have been reported to develop dilated cardiomyopathy[@b26].

Other genes related to CVD pathogenesis
---------------------------------------

The list of genes exhibiting sex-specific response to tobacco smoking includes a number of additional members for which there is significant clinical or mechanistic evidence, including evidence from transgenic animal studies, that they are linked with CVD pathogenesis. The gene with the largest expression change in female smokers is HMOX1 (haem oxygenase 1), well known for its antioxidant and anti-inflammatory properties as well as for its protective role against CVD[@b27][@b28][@b29]. HMOX1 is also known to protect against smoking-induced COPD[@b30], a disease for which there is strong evidence of differentially higher susceptibility in female smokers[@b1][@b5][@b6]. Another gene of interest is HDAC4 (histone deacetylase 4), differentially overmethylated in female smokers, which plays a global role in the epigenetic control of gene expression by modifying histones as well as non-histone proteins[@b31] and plays an important role in regulating hypertrophic responses[@b32]. Finally of particular note is the female-specific demethylation of the well known anti-apoptotic gene BCL2L1 (BCL2-like 1), which plays a key role in the regulation of platelet activation and apoptosis[@b33]. Among the consequences of platelet apoptosis is the production of microparticles, which are recognised to play an important role in inflammation, CVD, coagulation and angiogenesis[@b34].

The largest sex-related difference in the impact of smoking (absΔΔβ, last column in [Table 4](#t4){ref-type="table"}) is observed at 3 CpG sites associated with CACNA1D (calcium channel, voltage-dependent, L type, alpha 1D subunit). This gene encodes for the cav1.3 subunit of a voltage-gated, L-type calcium channel and human and animal studies strongly support its association with various pathological conditions, including cardiovascular and neurological disorders[@b35][@b36][@b37][@b38]. On a side note, it is of interest that cav1.3 physically interacts with the receptor of GABA~B~, with activation of the latter leading to an increase in the L-type calcium channel currents[@b39]. Given the key role of this receptor in the mechanism of addiction, it is possible that any sex-related variation in CACNA1D expression may be reflected in corresponding differences in susceptibility to nicotine addiction. In support of this idea, several lines of evidence indicate that females have a higher susceptibility to nicotine dependence, including faster progression to dependence, shorter and less frequent abstinence periods, greater difficulty to quit, and poorer response to smoking cessation treatments[@b38][@b40][@b41].

Other genes listed in [Table 4](#t4){ref-type="table"}, for which there is evidence of varying strength of links with different types of CVD, include TAGLN (transgelin[@b42]), SYNE1 (spectrin repeat containing, nuclear envelope 1)[@b43][@b44], IL32 (interleukin 32)[@b45], PLIN5 (perilipin 5)[@b46], HNRNPUL1 (Heterogeneous Nuclear Ribonucleoprotein U-Like 1)[@b47] and miR-30d[@b48]. Finally, [Table 4](#t4){ref-type="table"} shows a number of genes (C14orf43, C1orf21, ST3GAL1 and ZNF19) which do not have any function related to CVD pathogenesis, however they have been reported to be differentially expressed in patients with different types of CVD.

Molecular basis of sex-specific effects of tobacco smoke exposure
-----------------------------------------------------------------

The previous discussion shows that numerous genes among those found to be differentially altered in female smokers interact closely in the context of thrombin signaling in platelets and vascular/endothelial cells. While the molecular basis for such differential female susceptibility to tobacco smoke is not currently understood, there is strong evidence that thrombin signaling and hemostasis are subject to hormonal influences and it is possible that such influences may also modify the responses to tobacco smoking. Megakaryocytes and platelets express the estrogen and androgen receptors, and the coagulation cascade is known to be influenced by variations in the levels of female sex steroids[@b49][@b50][@b51], while it has been suggested that females have greater baseline platelet reactivity which may be attenuated by estrogens[@b51][@b52]. Furthermore, it has been reported that platelets from women are more responsive than those of men to thrombin agonists[@b51], and that females with atherosclerosis show higher PAR1-mediated platelet activation[@b53]. Sex hormones contribute to the modulation of additional genes related to CVD and may therefore also modify the impact of smoking. For example, the expression of HMOX1 under conditions of oxidative stress is modulated by estrogen receptor alpha[@b54], while estrogen receptor beta modulates the expression of HDAC4 under the influence of hypertrophic factors in rat cardiomyocytes[@b55].

Summarising the preceding discussion, a large number of genes which are known or suspected to play a role in the mechanism of CVD, and to modulate corresponding disease risks, have their expression or methylation in WBCs modified by smoking significantly more in females than in males. It is not known whether similar changes occur in other tissues of smokers. However we have recently reported that tobacco smoking causes similar changes in expression and CpG methylation in the Ah receptor repressor gene in WBCs and lung cells[@b10]. We have also shown that the genes which are differentially expressed or methylated in WBCs of smokers are closely related to many smoking-induced diseases regardless of their target tissue, implying that changes observed in blood cells may reflect more global effects. This conclusion is further supported by the concordance of the results presented in the present study with the conclusions of epidemiological studies which consistently point to a higher female susceptibility to tobacco-induced CVD. Furthermore, we also report analogous, although more limited, findings supporting higher female susceptibility to tobacco-induced COPD and nicotine addiction. Although our evaluation of the disease-relevance of the sex-specific DEGs and DMGs presented above did not include cancer, many of the signaling pathways discussed are also highly relevant to carcinogenesis[@b56]. It is noted that the current evidence regarding sex susceptibility to tobacco-related cancer is mixed[@b7][@b8][@b9][@b57].

In conclusion, the results presented here underline the utility of blood-based omics profiling for identifying health hazards associated with environmental exposures and suggest a potential for use of such data in identification of susceptible sub-groups.

Materials and Methods
=====================

The present report is based on data from the Envirogenomarkers project ([www.envirogenomarkers.net](http://www.envirogenomarkers.net)). Envirogenomarkers is a prospective case-control study nested within the European Prospective Investigation into Cancer and Nutrition study (EPIC-ITALY) and the Northern Sweden Health and Disease Study (NSHDS)[@b58][@b59], in which subjects asymptomatic at the time of enrolment provided a blood sample and information on dietary habits, lifestyle, health history etc. The EnviroGenomarkers project and its associated studies and experimental protocols were approved by the Regional Ethical Review Board of the Umea Division of Medical Research, for the Swedish cohort, and the Florence Health Unit Local Ethical Committee, for the Italian cohort, and all participants gave written informed consent. All methods were carried out in accordance with the approved guidelines.

Owing to the Envirogenomarkers project's design, some of the participating subjects had been selected on the basis of the fact that they went on to develop breast cancer or B-cell lymphoma 2--16 years after recruitment, however for the purposes of the present study they were all treated as apparently healthy. We have previously shown that inclusion of such subjects did not significantly affect the list of smoking-modified transcriptomic and epigenetic features[@b10]. Anthropometric measurements and lifestyle parameters had been collected through questionnaires at recruitment (1993--1998 for EPIC-ITALY; 1990--2006 for NSHDS). Information on smoking was obtained through questionnaires and included data on duration, number of cigarettes smoked per day and (only in Italy) pack-years. In addition, for a fraction of the subjects data on plasma cotinine concentration were also available. Details of the subjects involved in the present study are shown in [Table 1](#t1){ref-type="table"}. Sample collection, storage and processing procedures have been described elsewhere[@b58][@b59]. Based on the conclusions of a previously published pilot study[@b60], subjects were included in the study only if the processing of their blood samples and placement of their buffy coats in cold storage had been completed within 2 hours of collection so as to minimize effects on the transcriptomic profile.

RNA and DNA extraction from buffy coats, genome-wide analysis of gene expression (Agilent 4 × 44 K human whole genome microarray platform) and CpG methylation (Illumina Infinium HumanMethylation450 platform) and the corresponding data quality assessment and preprocessing, were conducted as described previously[@b60]. Cotinine levels (AUC) in plasma were measured by reverse-phase chromatography on an Acquity UPLC system (Waters Corporation, Milford, MA, USA) with a Acquity HSS T3 C18 10 mm × 2.1 mm, 1.8 μm, column (Waters) and a binary gradient elution comprising of water 0.1% formic acid and acetonitrile 0.1% formic acid for 19 min. Online analysis of the eluent was performed using a quadrupole time-of-flight mass spectrometer (QTOF-Ultima-MS; Waters) in the positive ion mode. Data were processed using Databridge and XCMS software (Waters). We confirmed the identity of cotinine with authentic standard and accurate mass.

Data analysis and the derivation of lists of expression probes and CpG sites which differed significantly between current and never smokers has been described in detail previously[@b10]. Briefly, linear mixed models were ran, using M values for DNA methylation or log2 intensities of mRNA expression as dependent variables, plus date of isolation, labeling, and hybridization for RNA expression, or date of analysis for methylation, as random variables. All analyses additionally adjusted for sex, age, BMI and cohort. Owing to the design of the EnviroGenomarkers project, future disease (breast cancer, B-cell lymphoma) and case-control status were also included as fixed variables. In the case of DNA methylation data, the models were also adjusted for blood cell composition estimated with a published algorithm[@b61]. Multiple testing was accounted for with high stringency by using Bonferroni or FDR Benjamini-Hochberg correction. This procedure led to the identification of lists, recently published[@b10], of 1,273 CpG sites (FDR \< 0.05) and 350 transcripts (FDR \< 0.10) which differ significantly in current relative to never smokers ([Suppl. Tables 1 and 2](#S1){ref-type="supplementary-material"}).

We looked for sex-related differences among the above mentioned expression and DNA methylation features by employing rank-based, non-parametric, statistical testing methodology based on the evaluation of the differences in the significance ranks of the probes in the two classes ([Fig. 2](#f2){ref-type="fig"}). Towards this end we first conducted current-versus-never smoker comparisons, using the same statistical models as previously, for all transcriptomic and epigenetic features (29,667 expression probes and 410,987 methylation probes, respectively) separately in males and females, ranking all features by the corresponding significance (p-value). Subsequently we extracted from these lists the rank values of the features which we had previously found to be significant in the mixed population (350 expression probes significant at FDR \< 0.10 and 1,273 CpGs significant at Bonferoni-corrected p \< 0.05) and calculated their differences between the two sexes. We thus derived a distribution of differences which conforms to the normality assumption (steep unimodal) and was used as basis in order search for differences that violate the null hypothesis that only non-sex-related differences are observed, i.e. signal rankings in sex-stratified analyses are equal. The statistic was calculated from the corresponding complementary cumulative distribution function (Survival Function)[@b62] which describes the probability that a variate takes a value greater than a particular number, taking as a significance threshold the value of p \< 0.05. The workflow of this analysis is described diagrammatically in [Fig. 1](#f1){ref-type="fig"}. The tool for the implementation of the statistical evaluation of sex-specific rank differences described above is publically available, under the name RIPOSTE ("Rank DrIven POpulation STatistical Evaluation"), on the Galaxy platform at <http://mebioinfo.ekt.gr/galaxy>, where instructions for its use are also given.

In order to check for any bias introduced by the difference in male and female population sizes on the selection of sex-specific signals, we implemented a permutation probabilistic approach (also illustrated in [Fig. 1](#f1){ref-type="fig"}, right) by randomly resampling 10 times the full population so as to extract subpopulations even with respect to sex and smoking status, subsequently applying to all subpopulations thus selected the same analytical workflow as described above. In each subpopulation we used all available male subjects (134) and an equal number of females selected randomly while maintaining unaltered the proportions of females from the different cohorts and with different smoking status. For each resampling we counted the number of significant (p \< 0.05 for rank difference) signals that came from among those obtained with the full male and female populations (shown in [Tables 2](#t2){ref-type="table"} and [3](#t3){ref-type="table"}).
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###### Study population and sex comparison of smoking exposure-related parameters.

                                                                       Males             Females
  ---------------------------------------- -------------------- ------------------- ------------------
                                                    N                   236                413
                                            age; mean (range)    51.0 (30.2--65.0)   52.8(29.6--74.9)
  cohort                                         NSHDS; N               171                228
  EPIC Italy; N                                     65                  185         
  BMI; mean (range)                         26.5 (19.0--39.5)    25.4(18.8--55.28)  
  smoking status                            current smokers; N      43 (18.2%)         100 (24.2%)
  former smokers; N                            102 (43.2%)          93 (22.5%)      
  never smokers; N                              91 (38.6%)          220 (53.3%)     
  duration of smoking                               N                   40                  90
  years, mean (s.d)                             31.8 (8.7)          30.6 (18.1)     
  p                                                0.49                             
  pack-years[\*](#t1-fn1){ref-type="fn"}            N                   14                  45
  mean (S.D)                                  582.9 (429.0)        356.6 (266.0)    
  p                                                0.06                             
  cigarettes/day                                 total N                42                  98
  ≤4, N                                         7 (16.7%)           24 (24.5%)      
  5--15, N                                      17 (40.5%)           50 (51%)       
  ≥25, N                                        18 (42.9%)          24 (24.4%)      
  p[\#](#t1-fn1){ref-type="fn"}                    0.2                              
  plasma cotinine                                   N                   40                  35
  AUC; mean (s.d.)                              33.7 (8.7)          28.1 (8.5)      
  p                                                0.85                             

^\*^Only EPIC Italy; ^\#^chi-squared test.

###### Expression probes and DEGs ranked by significance of sex specificity.

  Expression probe    Gene symbol   Gene name                                                      Rank by p-value in sex-stratified analysis   Effect size (ratio current/never smokers) in sex-stratified analysis                    
  ------------------ -------------- ------------------------------------------------------------- -------------------------------------------- ---------------------------------------------------------------------- ---------- ------ ------
  A_23_P120883           NMOX1      heme oxygenase (decycling) 1                                                     29,411                                                      31                                    2.82E-05   1.00   0.77
  A_23_P87013            TAGLN      transgelin                                                                       29,013                                                      74                                    3.86E-05   1.00   0.80
  A_24_P410453           SYNE1      spectrin repeat containing. nuclear envelope 1                                   28,573                                                     120                                    5.42E-05   1.00   0.81
  A_23_P23834             LGR6      leucine-rich repeat-containing G protein-coupled receptor 6                      27,005                                                      26                                    1.46E-04   1.49   0.72
  A_23_P136347            EPS8      epidermal growth factor receptor pathway substrate 8                             26,954                                                      16                                    1.50E-04   0.99   0.75
  A_24_P173754          C1orf21     chromosome 1 open reading frame 21                                               24,586                                                      24                                    6.54E-04   0.98   0.78
  A_23_P354387            MYOF      myoferlin                                                                        24,542                                                     111                                    7.06E-04   0.98   0.79
  A_23_P66881             RGS9      regulator of G-protein signaling 9                                               21,736                                                     118                                    3.29E-03   0.96   0.79
  A_24_P76644                                                                                                        20,804                                                     121                                    5.24E-03   0.98   0.88
  A_23_P86682             MYOF      myoferlin                                                                        19,999                                                      56                                    7.46E-03   0.96   0.78
  A_23_P43679            ZNF618     zinc finger protein 618                                                          19,852                                                      22                                    7.86E-03   0.96   0.84
  A_23_P1962            RARRES3     retinoic acid receptor responder (tazarotene induced) 3                          19,775                                                     113                                    8.49E-03   0.97   0.87
  A_23_P113161          C1orf21     chromosome 1 open reading frame 21                                               19,632                                                      47                                    8.80E-03   0.95   0.75
  A_24_P921823           TCF7L2     transcription factor 7-like 2 (T-cell specific. HMG-box)                         18,329                                                      7                                     1.53E-02   0.96   0.77
  A_23_P45831            CHD1L      chromodomain helicase DNA binding protein 1-like                                 19,187                                                    1,428                                   1.94E-02   0.98   0.93
  A_23_P48175           TMEM106C    transmembrane protein 106C                                                       18,096                                                     410                                    2.00E-02   0.96   0.88
  A_23_P39251            PLIN5      perilipin 5                                                                       229                                                      17,725                                  2.16E-02   1.34   1.05
  A_23_P200780           TGFBR3     transforming growth factor. beta receptor III                                    17,259                                                      94                                    2.47E-02   0.94   0.80
  A_23_P110791           CSF1R      colony stimulating factor 1 receptor                                             16,516                                                      49                                    3.23E-02   0.95   0.80
  A_32_P140475          KIAA1377    KIAA1377                                                                           72                                                      16,014                                  3.93E-02   0.82   0.97
  A_23_P213620          PPP2R2B     protein phosphatase 2. regulatory subunit B. beta                                16,049                                                     256                                    4.14E-02   0.94   0.86
  A_32_P75141                                                                                                        15,969                                                     240                                    4.24E-02   0.94   0.85
  A_23_P385105           PLCD4      phospholipase C. delta 4                                                         15,930                                                     354                                    4.48E-02   0.94   0.86
  A_24_P88763            LOXL3      lysyl oxidase-like 3                                                             15,979                                                     413                                    4.50E-02   0.95   0.89
  A_24_P9883          DKFZp761E198  DKFZp761E198 protein                                                               27                                                      15,524                                  4.61E-02   1.49   1.05
  A_23_P109171           BFSP1      beaded filament structural protein 1. filensin                                   15,892                                                     481                                    4.75E-02   0.93   0.84

###### CpG sites and DMGs ranked by significance of sex specificity.

  Probe        Gene symbol   Gene name                                                                        Rank by p-value in sex-stratified analysis   Males    Females    absΔΔβ = abs(Δβ~fem~ −Δβ~m)~                                          
  ------------ ------------- ------------------------------------------------------------------------------- -------------------------------------------- -------- ---------- ------------------------------ ------- ------- ------- ------- ------- -------
  cg03378003   SETD2         SET domain containing 2                                                                           410,615                      375     1.73E-08              84.23               84.24   0.00    84.92   83.59   1.33    1.33
  cg05713794   GP5           glycoprotein V (platelet)                                                                         399,753                      108     4.17E-08              81.42               81.44   −0.02   80.63   78.46   2.17    2.19
  cg13411554   CACNA1D       calcium channel. voltage-dependent. L type. alpha 1D subunit                                      398,828                      206     4.53E-08              29.34               29.25   0.08    34.69   28.22   6.47    6.39
  cg19028369   C3orf19       chromosome 3 open reading frame 19                                                                395,672                      613     6.06E-08               4.45               4.46    −0.01   4.29    4.59    −0.29   −0.29
  cg12611488   SKI           SKI proto-oncogene                                                                                394,498                       63     6.38E-08              78.07               77.99   0.08    82.74   78.36   4.39    4.31
  cg00436663   LOC400927                                                                                                       388,154                      171     1.07E-07               4.89               4.88    0.01    4.58    5.04    −0.45   −0.47
  cg17993335   DNMBP         dynamin binding protein                                                                           387,580                      886     1.19E-07              79.14               79.20   −0.06   80.01   78.03   1.99    2.05
  cg15743533   FAM110A       family with sequence similarity 110. member A                                                     369,751                      234     4.50E-07              11.46               11.50   −0.04   10.67   11.72   −1.05   −1.01
  cg17098415                                                                                                                   366,343                      190     5.79E-07               1.83               1.84    −0.02   1.93    2.20    −0.27   −0.25
  cg17532753   HDAC4         histone deacetylase 4                                                                             370,727                     5.606    6.26E-07              67.37               67.24   0.13    67.71   66.06   1.65    1.52
  cg25115829   SUZ12P        SUZ12 polycomb repressive complex 2 subunit pseudogene 1                                          179,095                      698     7.57E-07              73.04               72.23   0.81    75.55   72.97   2.58    1.77
  cg13543915                                                                                                                   360,064                      247     9.28E-07              61.82               61.91   −0.09   62.91   64.51   −1.60   −1.52
  cg09257526   IL6R          interleukin 6 receptor                                                                            359,954                     1.607    1.03E-06              20.44               20.52   −0.08   20.04   20.67   −0.62   −0.55
  cg12689529   KIRREL3       kin of IRRE like 3 (Drosophila)                                                                   341,191                      406     3.63E-06               6.84               6.91    −0.07   6.50    7.19    −0.69   −0.62
  cg13379236   EGF           epidermal growth factor                                                                           332,044                      256     6.73E-06              60.43               60.24   0.19    62.51   60.67   1.84    1.65
  cg06459104   EPB41L3       erythrocyte membrane protein band 4.1-like 3                                                      331,586                      341     6.98E-06              34.31               34.76   −0.46   33.82   38.07   −4.25   −3.79
  cg10232140   ERCC6         excision repair cross-complementation group 6                                                     328,904                      141     8.25E-06               1.54               1.50    0.05    1.78    1.32    0.46    0.41
  cg27430293                                                                                                                   152,757                     2.427    8.33E-06              34.11               33.26   0.85    36.95   34.92   2.03    1.18
  cg04985185   MBTPS1        membrane-bound transcription factor peptidase. site 1                                             321,636                      229     1.34E-05              83.83               83.59   0.24    84.90   82.76   2.14    1.89
  cg27171474   CDCA8         cell division cycle associated 8                                                                  329,032                      404     2.05E-05              84.89               84.78   0.11    86.22   85.01   1.21    1.09
  cg08202265   TAC1          tachykinin. precursor 1                                                                           314,885                      272     2.09E-05              87.55               87.23   0.31    88.45   85.15   3.30    2.99
  cg08528970                                                                                                                   311,563                     11.616   5.23E-05              13.11               13.34   −0.22   13.88   14.30   −0.41   −0.19
  cg02003183   CDC42BPB      CDC42 binding protein kinase beta (DMPK-like)                                                     296,555                      442     6.59E-05               8.34               8.14    0.21    6.33    5.57    0.76    0.55
  cg10665960   EPC2          enhancer of polycomb homolog 2                                                                    295,295                      491     7.13E-05               4.71               4.66    0.05    4.57    4.90    −0.33   −0.38
  cg26724967   IL32          interleukin 32                                                                                    184,670                      577     9.65E-05              59.76               60.34   −0.58   59.95   61.77   −1.82   −1.25
  cg07411111   TPD52L2       tumor protein D52-like 2                                                                          289,518                      998     1.04E-04              61.46               61.04   0.42    62.07   59.99   2.08    1.66
  cg09374353   EHD1          EH-domain containing 1                                                                            284,155                      321     1.36E-04              20.73               20.54   0.19    18.44   19.61   −1.18   −1.37
  cg23670519                                                                                                                   278,212                      616     1.94E-04              27.86               27.27   0.59    27.09   24.35   2.74    2.15
  cg05307957   ARID1A        AT rich interactive domain 1A (SWI-like)                                                          277,497                      132     1.97E-04               2.70               2.78    −0.08   2.99    3.38    −0.39   −0.31
  cg20305005   SCN2A         sodium channel. voltage-gated. type II. alpha subunit                                             273,040                      240     2.54E-04              58.37               57.96   0.42    58.65   56.27   2.38    1.96
  cg13989999   BCL2L1        BCL2-like 1                                                                                       268,258                     3.290    3.89E-04              47.52               47.93   −0.41   48.03   49.34   −1.31   −0.90
  cg06397161   SYNGR1        synaptogyrin 1                                                                                    262,200                     1.787    4.96E-04              42.48               42.79   −0.31   44.56   46.19   −1.63   −1.32
  cg06959021   TCHP          trichoplein. keratin filament binding                                                             255,728                      173     6.39E-04              58.68               58.28   0.40    61.71   59.85   1.86    1.45
  cg01911191                                                                                                                   253,223                     1.609    7.82E-04               2.70               2.62    0.08    2.34    2.07    0.27    0.19
  cg25446789   DTNB          dystrobrevin. beta                                                                                150,180                      257     8.25E-04              40.28               40.87   −0.60   40.07   42.21   −2.14   −1.55
  cg14179401                                                                                                                   249,065                      983     9.35E-04              33.38               33.60   −0.22   34.75   35.82   −1.07   −0.85
  cg08601457   FYN           FYN proto-oncogene. Src family tyrosine kinase                                                    242,282                      422     1.27E-03               7.11               7.28    −0.17   5.98    6.68    −0.70   −0.53
  cg16702313   C14orf43      chromosome 14 open reading frame 43                                                               239,378                      153     1.45E-03              60.71               61.00   −0.29   61.85   63.45   −1.60   −1.31
  cg13832372   LHX6          LIM homeobox 6                                                                                    239,227                      188     1.46E-03              10.96               11.42   −0.45   10.32   12.60   −2.28   −1.83
  cg24242519   FAM49A        family with sequence similarity 49. member A                                                      236,302                     1.218    1.77E-03              13.47               13.75   −0.28   13.51   14.61   −1.10   −0.82
  cg22638542   SEC22C        SEC22 homolog C. vesicle trafficking protein                                                      227,163                      329     2.60E-03              80.69               80.38   0.31    82.48   81.37   1.11    0.80
  cg01904243   C14orf43      chromosome 14 open reading frame 43                                                               225,047                      164     2.84E-03              13.97               14.22   −0.25   12.62   13.82   −1.20   −0.95
  cg06338710   GFI1          growth factor independent 1 transcription repressor                                               224,461                      205     2.92E-03              76.24               76.90   −0.66   77.50   79.53   −2.03   −1.38
  cg19048950   LOC100188                                                                                                       219,307                      463     3.72E-03              76.17               75.70   0.46    73.42   71.15   2.28    1.81
  cg02104700   S100P         S100 calcium binding protein P                                                                    217,731                      496     4.00E-03               2.42               2.49    −0.07   2.45    2.67    −0.22   −0.15
  cg15417641   CACNA1D       calcium channel. voltage-dependent. L type. alpha 1D subunit                                      215,584                       77     4.31E-03              50.18               48.86   1.32    53.39   46.64   6.76    5.44
  cg11222173   RPTOR         regulatory associated protein of MTOR. complex 1                                                  216,169                     1.025    4.38E-03              62.03               61.49   0.54    61.00   58.74   2.26    1.71
  cg08062087   C2orf66       chromosome 2 open reading frame 66                                                                215,666                      587     4.39E-03              69.15               68.61   0.54    70.09   68.06   2.03    1.49
  cg14950321   PLIN5         perilipin 5                                                                                       215,623                      763     4.44E-03              39.87               40.42   −0.55   41.31   43.13   −1.82   −1.27
  cg08778287   IGF1R         insulin-like growth factor 1 receptor                                                             214,383                      476     4.62E-03              33.41               32.78   0.64    31.37   28.84   2.54    1.90
  cg13698937   C4orf46       chromosome 4 open reading frame 46                                                                210,788                      694     5.45E-03              76.64               75.97   0.67    77.47   75.32   2.15    1.49
  cg00357551   FAM196B       family with sequence similarity 196. member B                                                     207,522                     1.016    6.33E-03              33.01               32.52   0.50    32.30   30.79   1.51    1.01
  cg04359840   XYLT1         xylosyltransferase I                                                                              206,167                      346     6.52E-03              47.27               47.85   −0.58   47.80   49.99   −2.19   −1.61
  cg21698310   PPP1R9B       protein phosphatase 1. regulatory subunit 15A                                                     203,847                      822     7.32E-03              10.66               10.89   −0.23   9.69    10.49   −0.81   −0.58
  cg00816037   FAM38A        family with sequence similarity 38. member A                                                      197,944                      281     9.10E-03               7.77               8.09    −0.33   6.69    7.77    −1.08   −0.75
  cg24488469                                                                                                                   192,915                      314     1.11E-02              15.97               16.30   −0.33   14.06   15.16   −1.09   −0.76
  cg12033822   SLC35C2       solute carrier family 35 (GDP-fucose transporter). member C2                                      189,184                     1.519    1.34E-02              26.76               27.15   −0.40   25.56   26.54   −0.98   −0.58
  cg22490254                                                                                                                   186,085                      396     1.45E-02              15.92               15.44   0.48    15.51   13.87   1.64    1.16
  cg26840970   ZNF19         zinc finger protein 19                                                                            315,231                      309     1.54E-02              69.05               68.76   0.29    71.08   68.75   2.33    2.04
  cg09608073   CHSY3         chondroitin sulfate synthase 3                                                                    184,657                      712     1.55E-02               9.31               9.50    −0.19   7.99    8.47    −0.48   −0.29
  cg19925780                                                                                                                   179,222                      134     1.85E-02              57.36               56.05   1.30    59.58   56.04   3.54    2.24
  cg25223634   C10orf26      chromosome 10 open reading frame 26                                                               172,484                      368     1.90E-02              37.56               38.21   −0.64   35.14   37.58   −2.43   −1.79
  cg00026474   ST3GAL1       ST3 beta-galactoside alpha-2.3-sialyltransferase 1                                                178,373                      842     1.96E-02              19.10               19.54   −0.44   19.23   20.63   −1.40   −0.96
  cg25114611   FKBP5         FK506 binding protein 5                                                                           362,777                      198     1.97E-02              30.27               30.36   −0.08   30.44   31.81   −1.37   −1.28
  cg01609214   MIR30D        microRNA 30d                                                                                      174,169                      418     2.24E-02              89.84               89.03   0.81    90.88   87.38   3.50    2.69
  cg21188533   CACNA1D       calcium channel. voltage-dependent. L type. alpha 1D subunit                                      173,743                       61     2.24E-02              43.74               41.82   1.91    52.19   43.74   8.45    6.54
  cg06627354   TRPM8         transient receptor potential cation channel. subfamily M. member 8                                173,046                      285     2.32E-02              65.91               65.21   0.70    64.45   61.66   2.79    2.10
  cg25722983   STK40         serine/threonine kinase 40                                                                        290,462                      740     2.36E-02              45.26               45.55   −0.29   46.40   47.91   −1.52   −1.22
  cg25233339   ATP1B3        ATPase. Na+/K+ transporting. beta 3 polypeptide                                                   250,770                      212     2.37E-02               3.69               3.79    −0.10   3.03    3.48    −0.45   −0.35
  cg00449189                                                                                                                   171,418                      702     2.49E-02              12.06               12.39   −0.33   10.75   11.51   −0.77   −0.44
  cg08287903   UGT8          UDP glycosyltransferase 8                                                                         169,875                      180     2.58E-02              48.84               48.15   0.69    51.00   48.24   2.76    2.06
  cg05055821                                                                                                                   168,762                      322     2.69E-02               9.90               9.65    0.26    9.44    8.67    0.77    0.52
  cg05525812                                                                                                                   171,414                     3.675    2.76E-02              16.95               17.39   −0.44   15.71   16.55   −0.84   −0.40
  cg20530056   IKBKE         inhibitor of kappa light polypeptide gene enhancer in B-cells. kinase epsilon                     168,953                     1.699    2.80E-02              63.75               64.26   −0.51   64.64   65.97   −1.33   −0.82
  cg01963224                                                                                                                   166,963                      102     2.84E-02              12.83               13.10   −0.28   11.88   12.94   −1.06   −0.78
  cg05548393   SLC30A8       solute carrier family 30 (zinc transporter). member 8                                             165,967                      483     2.98E-02              77.09               76.22   0.87    78.67   76.30   2.37    1.50
  cg24715767   PRDM2         PR domain containing 2. with ZNF domain                                                           165,652                      337     3.00E-02              57.80               57.13   0.67    61.48   59.19   2.29    1.62
  cg05603910   ANO9          anoctamin 9                                                                                       167,628                     3.304    3.10E-02              78.58               77.55   1.03    75.77   73.98   1.79    0.77
  cg16660971   RPTOR         regulatory associated protein of MTOR. complex 1                                                  163,969                      323     3.17E-02              72.09               71.01   1.08    71.01   66.95   4.06    2.98
  cg06361984   NDE1          nudE neurodevelopment protein 1                                                                   159,841                      809     3.69E-02              82.89               82.22   0.67    81.19   79.42   1.77    1.10
  cg17873451   LOC440925                                                                                                       157,993                      231     3.84E-02               4.11               4.26    −0.15   3.54    3.90    −0.37   −0.22
  cg03220447   NAV2          neuron navigator 2                                                                                159,803                     2.277    3.87E-02              12.43               12.70   −0.27   12.44   12.97   −0.53   −0.26
  cg05756780   IL6R          interleukin 6 receptor                                                                            156,614                     1.147    4.13E-02              23.32               23.63   −0.31   22.65   23.65   −1.00   −0.69
  cg02104644   SYT7          synaptotagmin VII                                                                                 158,677                     4.255    4.27E-02              19.47               20.07   −0.59   18.63   19.87   −1.24   −0.64
  cg08242636   CBFB          core-binding factor. beta subunit                                                                 155,174                     1.149    4.33E-02               5.10               5.25    −0.15   5.00    5.37    −0.37   −0.22
  cg22006825   HNRNPUL1      heterogeneous nuclear ribonucleoprotein U-like 1                                                  171,009                     17.624   4.41E-02              19.13               19.57   −0.45   19.20   19.75   −0.55   −0.10
  cg07201017   FLJ41350      LBX1 antisense RNA 1 (head to head)                                                               159,918                     6.965    4.48E-02              16.26               16.59   −0.33   15.82   16.34   −0.52   −0.19
  cg02571448   PCBP3         poly(rC) binding protein 3                                                                        151,595                      974     4.81E-02              41.12               41.91   −0.79   41.66   43.59   −1.93   −1.14
  cg24968629   CELSR1        cadherin. EGF LAG seven-pass G-type receptor 1                                                    177,517                      192     4.85E-02              74.90               73.75   1.15    70.52   65.45   5.07    3.92
  cg25474070   IL3           interleukin 3                                                                                     173,116                      895     4.92E-02              62.86               63.34   −0.47   64.15   65.74   −1.59   −1.12
  cg19859980   C1orf97       chromosome 1 open reading frame 97                                                                154,094                     4.225    4.92E-02               2.51               2.60    −0.09   2.59    2.74    −0.15   −0.06
  cg03699074   FAM38A        family with sequence similarity 38. member A                                                      150,341                      568     4.94E-02              14.23               14.69   −0.46   12.81   14.07   −1.26   −0.79

^\*^Methylation level (%); ^\#^Δβ = difference in % methylation of current-never smokers.

###### Female-specific DEGs/DMGs of potential relevance to CVD. and their expression/methylation changes observed in present study or reported clinical studies (where available).

  Gene         Direct evidence of links with CVD pathogenesis                                             Mechanistic basis of links with CVD       Current study   Vasclular inflam-mation[@b28]   Chronic artery occlussion[@b48]   Myocardial infarction[@b63]   Coronary heart disease[@b64]   Coronary artery disease[@b65]   Peripheral arterial disease[@b66]   Myocardial infarction[@b67]   Venous thrombo-embolism[@b68]   Atherosus-ceptibility[@b69]  
  ------------ ------------------------------------------------------------------------------------- --------------------------------------------- --------------- ------------------------------- --------------------------------- ----------------------------- ------------------------------ ------------------------------- ----------------------------------- ----------------------------- ------------------------------- ----------------------------- ---
  F2R (PAR1)   polymorphisms in human CVD[@b14]                                                         thrombin signaling/vascular haemostasis         down                                                                                                                                                   down                                                                                              down                                               
  GP5                                                                                                                                                    up                                                                                                                                                                                                                                                                                                       
  FYN          transgenic mice[@b19]                                                                                                                    down                                                                                                                                                                                                                                                      up                                              
  IGF1R                                                                                                                                                  up                                                                                                                                                                                                                                                                                      up               
  EGF                                                                                                                                                    up                                                                                                                                                                                                                                                                                                       
  EPS8         transgenic mice[@b24]                                                                                                                     up                                                                                                                                                                                                                                                                                                       
  RPTOR        transgenic mice[@b26]                                                                                                                     up                                                                                                                                                                                                                                                                                                       
  HMOX1        polymorphisms and differential expression in human CVD[@b28]; transgenic mice[@b28]                 anti-inflammatory                    down                                                     down                                                                                                                                                                                                                                               
  HDAC4                                                                                                        regulation of hypertrophy                                                                                                                                                                                                                                                                                                                            
  BCL2L1                                                                                                            anti-apoptotic                                              down                                                                                                                            up                                                                                                                                                  
  CACNA1D      polymorphisms in human CVD[@b37]; transgenic mice[@b35][@b36]                                      calcium signalling                                             up                                                                                                                                                                                                                                                                                 
  TANGLN       polymorphisms in human CVD[@b70]; transgenic mice[@b42]                                      VSMC/endothelial cell function              down                                                                                                                                                                                                                                                                                                        
  SYNE1        polymorphisms in human CVD[@b37]; transgenic mice[@b35][@b36]                                             down                                                                                                                                                                                                                                                     down                                                                            
  IL32         differential expression in human CVD[@b45]; transgenic mice[@b45]                                   pro-inflammatory                                             down                                                                                                                                                                                                                                                                                
  PLIN5        transgenic mice[@b46]                                                                               oxidative stress                                             down                                                                                                                                                                                                                                                                                
  HNRNPUL1     polymorphisms in human CVD[@b47]                                                                         unknown                                                 down                                                                                                                                                                                                                                                                                
  miR-30d      differential expression in human CVD[@b48]                                             regulation of cardiomyocyte apoptosis[@b71]                                up                                                               up                            down                                                                                                                                                                                
  C14orf43     differential expression in human CVD[@b61]                                                               unknown                                                 down                                                                                                                                                                                              down                                                                              
  C1orf21      differential expression in human CVD[@b59]                                                               unknown                         down                                                                                                                                                   down                                                                                                                                                 
  ST3GAL1      differential expression in human CVD[@b59]                                                               unknown                                                 down                                                                                                                            up                                                                                                                                                  
  ZNF19        differential expression in human CVD[@b59]                                                               unknown                                                  up                                                                                                                            down                                                                                                                                                 

The genes are listed in the order in which they are discussed in the main text. Col. 1 presents evidence based on human population and transgenic animal studies.

^\*^Expression; ^\#^methylation.
